ReviewNeurochemical research2003
Central GABAergic systems and depressive illness.
Review in Neurochemical research, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 54 citations in OpenAlex.
- Integrated Chemical, In Silico, and Functional Neurobehavioral Evaluation of Three Essential Oils in Acute Anxiety- and Depression-Related Mouse Models.Molecules (Basel, Switzerland) · 2026Article
- Pathophysiology of Depression: Stingless Bee Honey Promising as an Antidepressant.Molecules (Basel, Switzerland) · 2022Review
- Grading of Frequency Spectral Centroid Across Resting-State Networks.Frontiers in human neuroscience · 2018Article
- Relationships between GAT1 and PTSD, Depression, and Substance Use Disorder.Brain sciences · 2017Article
- Plasticity of Hippocampal Excitatory-Inhibitory Balance: Missing the Synaptic Control in the Epileptic Brain.Neural plasticity · 2016Review
- Repeated administration of imipramine modifies GABAergic transmission in rat frontal cortex.Journal of neural transmission (Vienna, Austria : 1996) · 2013Article
- Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.Neuropharmacology · 2012Review
- Association of the GABRD gene and childhood-onset mood disorders.Genes, brain, and behavior · 2010Article
- Wnt-5a modulates recycling of functional GABAA receptors on hippocampal neurons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2010Article
- Quantitative trait locus analysis identifies Gabra3 as a regulator of behavioral despair in mice.Mammalian genome : official journal of the International Mammalian Genome Society · 2010Article
- Down-regulated GABAergic expression in the olfactory bulb layers of the mouse deficient in monoamine oxidase B and administered with amphetamine.Cellular and molecular neurobiology · 2010Article
- Altered Organization of GABA(A) Receptor mRNA Expression in the Depressed Suicide Brain.Frontiers in molecular neuroscience · 2010Article
- Reduced conditioned fear response in mice that lack Dlx1 and show subtype-specific loss of interneurons.Journal of neurodevelopmental disorders · 2009Article
- GABAergic control of adult hippocampal neurogenesis in relation to behavior indicative of trait anxiety and depression states.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2007Article
- Normal [3H]flunitrazepam binding to GABAA receptors in the locus coeruleus in major depression and suicide.Brain research · 2006Article
- Tranylcypromine: new perspectives on an "old" drug.European archives of psychiatry and clinical neuroscience · 2006Review
- Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical depression and other mood disorders are relatively common mental illnesses but therapy for a substantial number of patients is unsatisfactory. For many years clinicians and neuroscientists believed that the evidence pointed toward alterations in brain monoamine function as the underlying cause of depression. This point of view is still valid. Indeed, much of current drug therapy appears to be targeted at central monoamine function. Other results, though, indicate that GABAergic mechanisms also might play a role in depression. Such indications stem from both direct and indirect evidence. Direct evidence has been gathered in the clinic from brain scans or postmortem brain samples, and cerebrospinal fluid (CSF) and serum analysis in depressed patients. Indirect evidence comes from interaction of antidepressant drugs with GABAergic system as assessed by in vivo and in vitro studies in animals. Most of the data from direct and indirect studies are consistent with GABA involvement in depression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.